Please select the option that best describes you:
Do you use MRD testing to guide maintenance therapy discontinuation in newly diagnosed non-high risk myeloma patients?
Please elaborate on both transplant-ineligible (not deferred) versus post-autologous transplant settings?
Answer from: Medical Oncologist at Academic Institution
Major bias, incoming!The short answer is: yes, I use MRD to guide de-escalation and ultimately discontinuation in standard-risk patients with myeloma.Much of that sentiment comes from our work at the University of Chicago called MRD2STOP, where we allow patients to stop treatment if they are sustain...
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
Patients with high-risk myeloma, whether defined by the IMS/IMWG or the somewhat controversial functional criteria, generally require ongoing treatment given the agents we have available; otherwise, they quickly relapse. It's easy to understand that there must be patients on the other end of t...
Answer from: Medical Oncologist at Academic Institution
Very little to add to the excellent answers by @Ben Derman and @Craig C. Hofmeister. For me, when I'm using Dara-Len maintenance, I do use MRD to guide Dara discontinuation (but continued lenalidomide) as done in PERSEUS...and for single-agent lenalidomide maintenance for standard-risk, I use a simi...